Stronghold (2.5 - 5 kg)
Active substance
ATC code
Species
Dogs.
Indications
• Treatment and prevention of flea infestations caused by Ctenocephalides spp. for one month following a single administration. This is as a result of the adulticidal, larvicidal and ovicidal properties of the product. The product is ovicidal for 3 weeks after administration. Through a reduction in the flea population, monthly treatment of pregnant and lactating animals will also aid in the prevention of flea infestations in the litter up to seven weeks of age. The product can be used as part of a treatment strategy for flea allergy dermatitis and through its ovicidal and larvicidal action may aid in the control of existing environmental flea infestations in areas to which the animal has access.
• Prevention of heartworm disease caused by Dirofilaria immitis with monthly administration. The veterinary medicinal product may be safely administered to animals infected with adult heartworms, however, it is recommended, in accordance with good veterinary practice, that all animals 6 months of age or more living in countries where a vector exists should be tested for existing adult heartworm infections before the administration of the veterinary medicinal product.
It is also recommended that dogs should be tested periodically for adult heartworm infections, as an integral part of a heartworm prevention strategy, even when the veterinary medicinal product has been administered monthly. This product is not effective against adult D. immitis.
• Treatment of ear mites (Otodectes cynotis).
• Treatment of biting lice infestations (Trichodectes canis) • Treatment of sarcoptic mange (caused by Sarcoptes scabiei)
• Treatment of adult intestinal roundworms (Toxocara canis).
Dose to be administered and administration route
The veterinary medicinal product should be administered as a single application of a single dose delivering a minimum of 6 mg/kg selamectin. When concurrent infestations or infections in the same animal are to be treated with the veterinary medicinal product, only one application of the recommended 6 mg/kg dose should be administered at any one time. The appropriate length of the treatment period for individual parasites is specified below.
Administer in accordance with the following table:
Dogs (kg) |
Pipette cap colour |
mg of selamectin dispensed |
Potency (mg/ml) |
Administered volume (nominal pipette size, ml) |
2.6–5.0 |
Violet |
30 |
120 |
0.25 |
Flea treatment and prevention
Following administration of the veterinary medicinal product, the adult fleas on the animal are killed, no viable eggs are produced, and larvae (found only in the environment) are also killed. This stops flea reproduction, breaks the flea lifecycle and may aid in the control of existing environmental flea infestations in areas to which the animal has access.
For the prevention of flea infestations, the veterinary medicinal product should be administered at monthly intervals throughout the flea season, starting one month before fleas become active. Through a reduction in the flea population, monthly treatment of pregnant and lactating animals will aid prevention of flea infestations in the litter up to seven weeks of age.
For use as part of a treatment strategy for flea allergy dermatitis the veterinary medicinal product should be administered at monthly intervals.
Prevention of heartworm disease
The veterinary medicinal product may be administered year-round or at least within one month of the animal’s first exposure to mosquitoes and monthly thereafter until the end of the mosquito season. The final dose must be given within one month after the last exposure to mosquitoes. If a dose is missed and a monthly interval between dosing is exceeded then immediate administration of the veterinary medicinal product and resumption of monthly dosing will minimise the opportunity for the development of adult heartworms.
When replacing another heartworm preventive veterinary medicinal product in a heartworm disease prevention programme, the first dose of the veterinary medicinal product must be given within a month of the last dose of the former medication.
Treatment of roundworm infections
A single dose of the veterinary medicinal product should be administered.
Treatment of biting lice
A single dose of the veterinary medicinal product should be administered.
Treatment of ear mites
A single dose of the veterinary medicinal product should be administered. Loose debris should be gently removed from the external ear canal at the time of treatment. A further veterinary examination 30 days after treatment is recommended as some animals may require a second treatment.
Treatment of sarcoptic mange
For complete elimination of the mites, a single dose of the veterinary medicinal product should be administered for two consecutive months.
Method and route of administration: Spot-on use.
Apply to the skin at the base of the neck in front of the shoulder blades.
How to apply:
Remove the pipette from its protective package | |
Holding the pipette upright, firmly depress the cap to puncture the applicator seal, then remove the cap | |
Part the hair at the base of your animal’s neck in front of the shoulder blades to expose a small area of skin | |
Apply the tip of the pipette directly to the skin without massaging. Squeeze the pipette firmly to empty the contents in one spot. Avoid contact between the product and your fingers. |
Adverse reactions
Dogs:
Rare (1 to 10 animals / 10,000 animals treated): | application site hair changes1 |
Very rare (<1 animal / 10,000 animals treated, including isolated reports): | neurological signs (including seizures)2 |
1Local temporary clumping of the hair at the application site and/or an occasional appearance of a small quantity of a white powder which typically disappear within 24 hours of treatment administration and does not affect either the safety or efficacy of the veterinary medicinal product.
2Reversible as with other macrocyclic lactones.
Reporting adverse events is important. It allows continuous safety monitoring of a veterinary medicinal product. Reports should be sent, preferably via a veterinarian, to either the marketing authorisation holder or its local representative or the national competent authority via the national reporting system. See also section “Contact details” of the package leaflet.